We sought to evaluate C-reactive protein (CRP) and troponin T (TnT) as predictors of risk of the individual end points of mortality and myocardial infarction (MI) in a large cohort of patients with acute coronary syndrome (ACS). BACKGROUND Both CRP and TnT predict risk of future coronary events in patients with ACS. However, the relationships between the levels of the markers and the individual end points are still unclear.
Inflammation has an essential role in the pathogenesis of atherosclerosis (1) and is also a consequence of myocardial damage. Elevated markers of inflammatory activity are associated with an increased risk of future cardiovascular events in healthy individuals (2, 3) and in patients with stable (4) and unstable coronary artery disease (CAD) (5) (6) (7) (8) . In unstable CAD, C-reactive protein (CRP) elevation on hospital admission has been shown to be an independent predictor of mortality (5) (6) (7) (8) . However, the association between the CRP level and the early risk of myocardial infarction (MI) in unstable CAD has not been established, because most studies have presented small patient numbers and combined end points (4, 7, 9, 10) . Numerous previous studies have shown that troponin elevation is associated with an impaired outcome in patients with unstable CAD (11) . Also, few studies have had a sample size and event rate allowing the separate evaluation of subsequent death and MI in relation to troponin levels. The present pre-defined analyses from the Global Use of Strategies To Open occluded arteries trial IV (GUSTO-IV) (12) is the largest study on the associations between baseline levels of troponin T (TnT) and high-sensitivity CRP and the separate events of death and MI in patients with unstable CAD.
METHODS
Patient selection and randomized treatment. The GUSTO-IV trial included 7,800 patients with unstable CAD from 458 centers in 24 countries during 1999 and 2000. The detailed design and main results of the trial have been published (12) . Eligible patients were Ն21 years of age with one or more episodes of angina lasting Ն5 min within 24 h of admission and either a positive cardiac TnT or TnI test (above the upper limit of normal for the local assay) or Ն0.5 mm of transient or persistent ST-segment depression. The study was conducted in a double-blind fashion with patients randomly assigned to three treatment groups: abciximab infusion for 24 h or 48 h or corresponding placebo infusion. All patients received aspirin, 150 to 325 mg/day orally for long-term treatment, as well as either unfractionated heparin infusion for 48 h (n ϭ 6,826) or subcutaneous dalteparin every 12 h for five to seven days (n ϭ 974). Coronary angiography was not to be performed during or within 12 h after completion of study agent infusion. Laboratory analyses. Venous blood samples were collected in evacuated tubes through a direct venous puncture at baseline and 8, 16, 24, 36, and 48 h after randomization. After centrifugation, serum was frozen at Ϫ20°C in aliquots and sent for central laboratory analyses of creatine kinase, MB isoenzyme (CK-MB) levels. One aliquot of the serum samples at baseline was stored at Ϫ70°C and sent in batches of 500 to the Department of Clinical Chemistry, Uppsala, Sweden, for analyses of TnT and CRP. One batch was unfortunately lost during transportation. The levels of TnT were determined by a third-generation assay on an Elecsys (Roche Diagnostics, Basel, Switzerland), with the detection limit at 0.01 g/l and a total coefficient of variance (CV) of 8% at 0.05 g/l and 4.1% to 6.0% between 0.1 and 11 g/l. The CRP concentrations were measured with a chemiluminescent enzyme-labeled immunometric assay (Immulite CRP, Diagnostic Products Corp., Los Angeles, California). The detection limit was 0.1 mg/l, with a total CV of 5.6% at 2 mg/l and 5% at 10 mg/l. Definition of end points. A 12-lead electrocardiogram was obtained at randomization, 48 h, or seven days and at 30 days. Myocardial infarction was defined as either a new, significant Q-wave (Ն0.04 s or at least a quarter of the R wave amplitude in two or more contiguous leads) or CK-MB at least three times the upper limit of normal. For patients with CK-MB elevation at study entry, a new episode of chest pain in combination with a new CK-MB elevation was required for MI diagnosis during the initial seven days, as presented in detail in the GUSTO-IV-ACS report (12) . After coronary artery bypass graft surgery, a new, significant Q-wave was the only criterion. A clinical end-point committee blinded to treatment assignment adjudicated all suspected cases of MI.
Statistical methods. The present evaluation of CRP and TnT on outcome was performed using pre-defined analyses. The material was divided into strata based on quartiles of the respective CRP and TnT levels. For continuous variables, means were expressed with one standard deviation, and for variables not normally distributed, medians were shown with 25th to 75th percentiles. The outcomes of death and/or MI at 48 h, seven days, and 30 days were compared between the different strata of patients. Differences were evaluated with the chi-square test (linear by linear association). Odds ratios (OR), with 95% confidence intervals (CI), were presented. A p value Ͻ0.05 was considered statistically significant. The independence of relationships between the patient strata of the two markers and the outcomes of death/MI, death, and MI at 30 days was assessed in three different models of multiple logistic regression analysis. A number of known risk factors were entered into the models: age, male gender, body weight, smoking, previous angina, stroke, heart failure, diabetes mellitus, hypertension, hypercholesterolemia, previous revascularization, previous MI, current treatment with beta-blockers and angiotensin-converting enzyme inhibitors, aspirin treatment before inclusion, ST-segment depression Ն0.5 mm, and randomized treatment (abciximab for 24 or 48 h or placebo). Model 1 also included quartiles of TnT and CRP. Model 2 included the bottom versus the three upper quartiles of either marker in addition to the quartiles of the other variable. Finally, model 3 included the top versus the three lower quartiles in addition to the quartiles of the other variable. Additional logistic regression analyses were performed to test for the interaction between TnT and CRP quartiles.
RESULTS
The mean age of the study population was 65.2 Ϯ 11.3 years, and 36.7% were females (Tables 1 and 2 ). STsegment depression Ͼ0.5 mm was observed in 80.1%, and troponin T was Ͼ0.1 g/l in 47.3% of the patients, as inclusion was based on either ST-segment depression or a positive troponin test. The median time from the onset of the qualifying episode of ischemic chest pain to randomization was 9.5 h (range 5.0 to 16.6). During infusion of the study agent (48 h), only 1.8% of the patients (n ϭ 131) underwent revascularization, as intended by the protocol. However, at 30-day follow-up, 29.3% of the patients (n ϭ 2,088) had undergone such a procedure. Troponin T, CRP, and their relationships to baseline characteristics. Troponin T analyses for 7,115 patients (91.2%) and CRP analyses for 7,108 patients (91.1%) were available. The TnT levels ranged from 0 to 17.3 g/l, and the quartile limits were 0.01, 0.12, and 0.47 g/l. The range of CRP levels was 0 to 489 mg/l, with quartile limits of 1.84, 3.96, and 9.62 mg/l. The Spearman correlation coefficient for the concordance of the two markers was 0.24. The baseline characteristics for the strata of patients based
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ϭ acute coronary syndrome CAD ϭ coronary artery disease CI ϭ confidence interval CK-MB ϭ creatine kinase, MB isoenzyme CRP ϭ C-reactive protein CV ϭ coefficient of variance GUSTO-IV ϭ Global Use of Strategies To Open occluded arteries trial IV MI ϭ myocardial infarction OR ϭ odds ratio TnT ϭ troponin T 917 JACC Vol. 41, No. 6, 2003 James et al. March 19, 2003:916-24 Troponin and CRP in Acute Coronary Syndrome on quartiles of both markers are shown in Tables 1 and 2 . Both markers were positively correlated to age and current smoking and negatively to hypercholesterolemia, a history of angina pectoris, and hypertension. In addition, CRP had a positive correlation to diabetes and heart failure. Troponin T in relation to outcome. The rate of the primary combined end point of death or MI (Fig. 1a) in the GUSTO-IV-ACS study was increasing with higher TnT quartiles at all time points of follow-up (p Ͻ 0.001). Also, mortality was markedly increasing with increased TnT quartiles from 1.1% to 7.4% between the first and fourth quartile at 30 days (Fig. 1b) . There was a large increase from the first to second quartile (1.1% vs. 3.7%) and from the third to fourth quartile (3.7% vs. 7.4%). The rate of MI was increasing from the first to second quartile (2.5% vs. 6.7% at 30 days). No further increase was observed between the upper three quartiles (Fig. 1c) . There was even a trend toward a lower rate of MI in the fourth quartile as compared with the third quartile (5.6% vs. 7.2%). On multiple logistic regression analysis, increasing TnT quartile was independently related to both death (OR 1.63, 95% CI 1.43 to 1.87) and MI (OR 1.23, 95% CI 1.11 to 1.37) at 30 days (Table 
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. Also, when entered into the regression model as a continuous variable, TnT was a significant independent predictor of mortality (OR 1.25, 95% CI 1.10 to 1.42). The first and third quartile limits independently predicted mortality, whereas only the first quartile limit independently predicted MI. The relationship between TnT and CRP levels and cardiac events was similar when performed only for the 5,756 patients included with the ST-segment depression criterion. In this group, the 30-day mortality rates for increasing TnT quartiles were 1.1%, 3.8%, 4.9%, and 8.6% (p Ͻ 0.001) and the corresponding MI rates were 2.6%, 7.0%, 8.0%, and 6.6% (p Ͻ 0.001). There was no difference in outcome at 30-day follow-up between the randomized treatment groups at different quartiles of TnT. C-reactive protein in relation to outcome. The rate of the primary combined end point-death or MI-was significantly increasing with higher CRP quartiles at 30 days: 7.1%, 7.3%, 8.1%, and 10.5% (p ϭ 0.001) (Fig. 2a) . This difference was entirely driven by the difference in mortality, which was observed already at 48 h (Fig. 2b) . At 30 days, mortality increased from 2% in the first quartile to 6.3% in the fourth quartile, with increases also from the first to second and from the third to fourth quartiles. However, at no time point was there any relationship between the rate of MI and the quartiles of CRP (Fig. 2c) . On multiple logistic regression analysis (Table 3) , increasing CRP quartiles independently predicted 30-day mortality (OR 1.19, 95% CI 1.05 to 1.35). C-reactive protein, entered into the logistic regression analysis as a continuous variable, was also an independent predictor of 30-day mortality (OR 1.005, 95% CI 1.00 to 1.009). However, there was no relationship between increasing CRP quartiles and the rate of MI at 30 days (OR 0.94, 95% CI 0.85 to 1.04). Mortality at 30 days was also independently predicted by the first quartile limit (Ͼ1.84 vs. Յ1.84). For the 5,756 patients included with ST-segment depression, the outcome was similar at 30 days for the strata of patients based on increasing CRP quartiles. Thus, in this subpopulation, the 30-day mortality rates were 2.2%, 3.4%, 4.2%, and 6.8% (p Ͻ 0.001), and the corresponding MI rates were 5.8%, 5.0%, 5.6%, and 6.4% (p ϭ 0.4). There was no difference in outcome at 30-day follow-up between the randomized treatment groups at different quartiles of CRP. Combination of TnT and CRP. As both TnT and CRP were independent predictors of 30-day mortality (Table 3) , its relationship to the combination of the markers was also evaluated. The highest mortality at 30 days (9.1%) was found in patients with both markers in the top quartiles (Table 4) , and the lowest mortality (0.3%) was found in patients with both makers in the bottom quartiles. 
DISCUSSION
In concordance with other studies, the current study shows that both TnT and CRP are significant predictors of an adverse outcome in the early phase after an episode of acute coronary syndrome (ACS) (6, 8, 9) . In contrast to previous studies, both CRP and TnT levels were available from a sufficiently large number of patients to allow prospective evaluation of their relationships to mortality and risk of MI All three models included age, male gender, body weight, smoking, previous angina, stroke, heart failure, diabetes mellitus, hypertension, hypercholesterolemia, previous revascularization, previous myocardial infarction, current treatment with beta-blockers and angiotensin-converting enzyme inhibitors, aspirin treatment before inclusion, ST-segment depression Ն0.5 mm, and randomized treatment (abciximab for 24 or 48 h or placebo). *Patient strata based on quartiles of troponin T: Յ0.01, 0.01-0.12, 0.12-0.47, and Ͼ0.47 g/l. †Patient strata based on quartiles of CRP: Յ1.84, 1.84 -3.96, 3.96 -9.62, and Ͼ9.62 mg/l. ‡Quartiles of the other marker were included in the analysis. CI ϭ confidence interval; CRP ϭ C-reactive protein; MI ϭ myocardial infarction; OR ϭ odds ratio; TnT ϭ troponin T.
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Troponin and CRP in Acute Coronary Syndrome separately. Furthermore, the independent associations to outcome could also be demonstrated in multivariable analyses.
There was a very low 30-day mortality (1.1%) and MI rate (2.5%) in patients without detectable TnT, in agreement with previous studies (6,13). The mortality increased with higher quartiles of TnT. In accordance with the FRagmin during InStability in Coronary artery disease (FRISC-II) study (14) , any detectable TnT was associated with a marked increased rate of MIs, probably reflecting a thrombotic coronary lesion, with increased risk of subsequent occlusion and/or downstream embolization. However, patients in the highest compared with the two middle quartiles had a trend toward a lower rate of MI, probably due to a larger proportion of already completed MIs. Thus, increasing TnT levels are associated with a continuous rise in mortality, whereas any detectable TnT (i.e., Ͼ0.01 g/l) is associated with a raised risk of MI without a significant further risk at higher TnT levels. The frequent core laboratory analyses of CK-MB and the rigorous MI definition requiring a new episode of chest pain and new CK-MB elevation make the possibility that an MI has resulted from the same event as the initial TnT elevation unlikely.
In the present study, increased CRP levels during the acute stage of unstable CAD were related to increased mortality, in accordance with previous findings (5) (6) (7) (8) . In this large patient cohort, this relation to increased mortality was evident early and further accentuated throughout 30-day follow-up. However, there was no association between the CRP levels and the risk of MI, which has not been shown previously. No previous study on inflammatory markers in ACS has contained a sufficient number of patients, enabling separation of the end points of death and MI. However, for the placebo group (n ϭ 447) in the Chimeric 7E3 AntiPlateleT in Unstable angina REfractory to standard treatment (CAPTURE) trial, there was an increased mortality in patients with CRP Ͼ10 mg/l, without a corresponding rise in the occurrence of MI during the initial six months (7) . Also, the FRISC trial (n ϭ 965) reported an increased mortality for patients with increasing CRP levels, without any increase in the combined end point of death/MI (5), indicating the absence of a relationship between CRP levels and MI over a follow-up period of five months.
The use of a positive troponin test as an inclusion criterion might have influenced the associations between troponin levels and outcome, but this seems unlikely given that the relationship between TnT and CRP levels and cardiac events was similar when the test was performed only in the 5,756 patients included with the ST-segment depression criterion. What might be the reason for the relationship between CRP and subsequent mortality, but not MI, in the acute phase of unstable CAD, despite the well-established relationship between CRP elevation and subsequent coronary events in the chronic phase of atherosclerotic disease (2, (15) (16) (17) ? In the acute phase of unstable CAD, the pronounced elevation of CRP is transient and likely related to an acute-phase reaction (18) . Some patients with unstable CAD might have a hyper-responsiveness of the inflammatory system, which might exaggerate the acute-phase reaction and increase the immune system reaction (19) . Such a mechanism is supported by the observations of colocalization of CRP and activated complement in infarctrelated myocardium (20) . C-reactive protein may contribute to inflammation by activation of complement, which may, in turn, mediate myocardial damage, induce arrhythmias, and provoke contractile dysfunction (21) . Such an interpretation is in accordance with the relationships between the CRP level and the occurrence of cardiac rupture, left ventricular aneurysm formation, and mortality after acute MI (22) . The pronounced CRP elevation in unstable CAD might also indicate a process different from the low-grade CRP elevation in the chronic phase of atherosclerosis, which is associated with subsequent coronary events among healthy individuals (2, 16, 23) and after MI (17) . In unstable CAD and chronic atherosclerotic disease, there is a lasting elevation of the fibrinogen level (18) , which might indicate an underlying chronic low-grade inflammatory condition that is associated with a raised risk of later MI in both conditions.
Despite the prognostic capacity of TnT regarding mortality, adding CRP further improved the risk stratification. On multivariable analysis, when correcting for a large number of clinical risk factors, including TnT, increasing CRP quartiles was an independent predictor of mortality. With TnT and CRP as continuous variables, the ORs were lower but still significant. Based on the present findings, the combination of these two markers seems to identify three (Tables 4 and 5 ) : one very low-risk group without detectable TnT and CRP Ͻ1.84 mg/l; one medium-risk group; and one high-risk group with TnT Ͼ0.47 g/l and CRP Ͼ9.62 mg/l, with corresponding 30-day mortality rates of Ͻ0.3%, 3% to 5%, and Ͼ9%, respectively. These strata could prove useful in the selection of more aggressive treatment for individual patients. Similar relationships were found by Morrow et al. (8) in the Thrombolysis In Myocardial Infarction (TIMI)-11A substudy (n ϭ 437), in which rapid TnT assays with a detection limit of 0.2 g/l were used. However, in the current larger study, the influence of CRP levels on mortality was evident even in patients without any detectable TnT. Study limitations. Our trial lacked information on left ventricular function, cholesterol levels, and the type of lipid-lowering treatment, all of which have importance for subsequent mortality in the study population. Patients with hypercholesterolemia at baseline had a statistically significant (p Ͻ 0.001) lower median level of CRP (3.7 vs. 4.1 mg/l), supporting the evidence that statin treatment reduces CRP levels among survivors of MI (24) . However, it is still unknown whether this effect has any bearing on the improvement in outcome by statin treatment. In the present study, the presence of hypercholesterolemia at baseline did not influence the outcome. The causes of death were not available, thus eliminating all opportunities for further analysis of the mechanisms of mortality in the different groups. GUSTO-IV included ACS patients with selected risk criteria. The results are therefore primarily applicable to a patient population with similar characteristics. However, these characteristics are representative of a more general ACS population (25) . The event rate in GUSTO-IV was also similar to previous trials on unstable CAD when differences in definitions of MI are taken into consideration. Clinical implications. In ACS, the levels of troponin and CRP provide important, different, and complementary prognostic information. With increasing levels of any of the markers, there is a commensurate rise in mortality. At any detectable troponin, there is also a raised risk of a later MI. The combination of both markers allows the best prediction of mortality. The use of the combination of these markers will provide an important tool for the selection of patients for clinical trials and also for identification of patients for different treatment alternatives.
